Study of FCRL5 protein in multiple sclerosis and treatment response
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at a protein called FCRL5 in the blood of people with multiple sclerosis (MS), as well as healthy volunteers and people with Sjögren's syndrome. The goal is to understand how this protein relates to MS and how it might affect treatment response. If you have MS and are about to start a new treatment, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple sclerosis (MS) diagnosed by a doctor using the latest McDonald criteria.
- You are between 18 and 80 years old.
- You are about to start a new MS treatment or switch treatments.
- You have not had an MS relapse in the last 3 months.
- You have not taken steroids (like prednisone) in the last 3 months.
- You are not taking other immune-suppressing drugs for conditions other than MS.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks specific proteins in spinal fluid to see whether they can predict how multiple sclerosis (or related symptoms like optic neuritis) may go over time. It may help doctors better estimate prognosis using results from tests you may already be having.
This study looks at different immune cells in blood and, sometimes, spinal fluid (CSF) to understand what’s driving multiple sclerosis (MS) or early MS-like symptoms. Your participation may help researchers better explain the disease and potentially improve how it’s diagnosed or treated.
This study looks at genetic information and blood test signals to understand why some people with early MS develop a worse outcome. It may help doctors predict who is at higher risk and better understand disease mechanisms.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.